Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacques Irani

Showing results (51-60 of 112) with videos related to

Pageof 12
Sort By:
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|October 31, 2006
[Macroscopic haematuria after transurethral resection of the prostate]Guillaume Normand, Julien Guignet, Raphaël Briffaux, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|June 1, 2006
[Has the initial or secondary status of the bladder tumors T1 G3 a prognostic impact?]Frédéric Ouaki, Jacques Irani, Christophe Pires, et al.
The Prostate|July 13, 2011
Biological significance of perineural invasion (PNI) in prostate cancerGaëlle Fromont, Julie Godet, Christophe Pires, et al.
Histopathology|October 13, 2009
Differential expression of the semaphorin 3A pathway in prostatic cancerMokrane Yacoub, Alix Coulon, Olivier Celhay, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|March 11, 2006
[Does the initial or secondary status of T1G3 bladder tumours have a prognostic impact?]Frédéric Ouaki, Jacques Irani, Christophe Pires, et al.
World Journal of Urology|June 3, 2018
Epidemiology, biology and treatment of sarcomatoid RCC: current state of the artCedric Lebacle, Aydin Pooli, Thomas Bessede, et al.
Clinical Therapeutics|May 10, 2005
The role of luteinizing hormone-releasing hormone therapy in locally advanced prostate cancer and biochemical failure: considerations for optimal usePierre Teillac, Aldo V Bono, Jacques Irani, et al.
The Journal of Urology|January 15, 2013
Is an extended 20-core prostate biopsy protocol more efficient than the standard 12-core? A randomized multicenter trialJacques Irani, Pascal Blanchet, Laurent Salomon, et al.
Clinical Transplantation|February 18, 2020
Temporary contraindication of obese recipients in kidney transplantation: A new morphometric tool for decision supportUgo Pinar, Yohann Renard, Dina Bedretdinova, et al.
Urologia Internationalis|September 16, 2009
Percentage of positive biopsy cores at the onset of hormone therapy for prostate cancer: prognostic significanceGuillaume Normand, Olivier Celhay, Raphaël Briffaux, et al.
Pageof 12

Showing results (51-60 of 112) with videos related to

Sort By:
Pageof 12
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|October 31, 2006
[Macroscopic haematuria after transurethral resection of the prostate]Guillaume Normand, Julien Guignet, Raphaël Briffaux, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|June 1, 2006
[Has the initial or secondary status of the bladder tumors T1 G3 a prognostic impact?]Frédéric Ouaki, Jacques Irani, Christophe Pires, et al.
The Prostate|July 13, 2011
Biological significance of perineural invasion (PNI) in prostate cancerGaëlle Fromont, Julie Godet, Christophe Pires, et al.
Histopathology|October 13, 2009
Differential expression of the semaphorin 3A pathway in prostatic cancerMokrane Yacoub, Alix Coulon, Olivier Celhay, et al.
Progres En Urologie : Journal De L'Association Francaise D'Urologie Et De La Societe Francaise D'Urologie|March 11, 2006
[Does the initial or secondary status of T1G3 bladder tumours have a prognostic impact?]Frédéric Ouaki, Jacques Irani, Christophe Pires, et al.
World Journal of Urology|June 3, 2018
Epidemiology, biology and treatment of sarcomatoid RCC: current state of the artCedric Lebacle, Aydin Pooli, Thomas Bessede, et al.
Clinical Therapeutics|May 10, 2005
The role of luteinizing hormone-releasing hormone therapy in locally advanced prostate cancer and biochemical failure: considerations for optimal usePierre Teillac, Aldo V Bono, Jacques Irani, et al.
The Journal of Urology|January 15, 2013
Is an extended 20-core prostate biopsy protocol more efficient than the standard 12-core? A randomized multicenter trialJacques Irani, Pascal Blanchet, Laurent Salomon, et al.
Clinical Transplantation|February 18, 2020
Temporary contraindication of obese recipients in kidney transplantation: A new morphometric tool for decision supportUgo Pinar, Yohann Renard, Dina Bedretdinova, et al.
Urologia Internationalis|September 16, 2009
Percentage of positive biopsy cores at the onset of hormone therapy for prostate cancer: prognostic significanceGuillaume Normand, Olivier Celhay, Raphaël Briffaux, et al.
Pageof 12